Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Leases (2019 - 2025)

Autolus Therapeutics' Current Leases history spans 7 years, with the latest figure at $4.6 million for Q4 2025.

  • For Q4 2025, Current Leases rose 52.27% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $4.6 million, up 52.27%, while the annual FY2025 figure was $4.6 million, 52.27% up from the prior year.
  • Current Leases reached $4.6 million in Q4 2025 per AUTL's latest filing, down from $4.8 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $6.2 million in Q2 2023 to a low of $3.0 million in Q1 2025.
  • Average Current Leases over 5 years is $4.4 million, with a median of $4.5 million recorded in 2021.
  • Peak YoY movement for Current Leases: surged 55.97% in 2023, then tumbled 40.67% in 2024.
  • A 5-year view of Current Leases shows it stood at $4.5 million in 2021, then increased by 13.14% to $5.0 million in 2022, then increased by 0.3% to $5.1 million in 2023, then crashed by 40.67% to $3.0 million in 2024, then soared by 52.27% to $4.6 million in 2025.
  • Per Business Quant, the three most recent readings for AUTL's Current Leases are $4.6 million (Q4 2025), $4.8 million (Q3 2025), and $3.3 million (Q2 2025).